Loading
A phase 2 trial of Botensilimab in colorectal cancer, run by Agenus Inc., active and no longer recruiting.
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer is a phase 2 interventional study registered as NCT05608044 by Agenus Inc., with 234 participants enrolled, started 2022-11-30 and due to reach its primary completion in 2027-09. Interventions recorded: Botensilimab, Balstilimab, Standard of Care. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Agenus, Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Balstilimab, Colorectal cancer.
Shares Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Botensilimab, Balstilimab, Immune checkpoint inhibitors.
Shares Agenus, Botensilimab, Balstilimab, Hot vs cold tumours.